Aurinia Pharmaceuticals - AUPH Stock Forecast, Price & News

5 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last twelve months. There are currently 1 hold rating and 4 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" AUPH shares.
View AUPH analyst ratings or view top-rated stocks.

5 analysts have issued 1-year price targets for Aurinia Pharmaceuticals' stock. Their AUPH share price forecasts range from $11.00 to $14.00. On average, they predict the company's stock price to reach $12.50 in the next twelve months. This suggests a possible upside of 33.4% from the stock's current price.
View analysts price targets for AUPH or view top-rated stocks among Wall Street analysts.

Aurinia Pharmaceuticals' stock was trading at $4.32 at the beginning of the year. Since then, AUPH shares have increased by 116.9% and is now trading at $9.37.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, February 27th 2023.
View our AUPH earnings forecast.

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) released its quarterly earnings results on Thursday, November, 3rd. The biotechnology company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.12. The biotechnology company earned $55.78 million during the quarter, compared to analysts' expectations of $38.11 million. Aurinia Pharmaceuticals had a negative trailing twelve-month return on equity of 26.03% and a negative net margin of 89.50%.

Aurinia Pharmaceuticals updated its fourth quarter 2022 earnings guidance on Friday, January, 6th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $28.40 million-$28.40 million, compared to the consensus revenue estimate of $26.97 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Advanced Micro Devices (AMD), Micron Technology (MU), Sorrento Therapeutics (SRNE), Cara Therapeutics (CARA), Exelixis (EXEL), AbbVie (ABBV), Amarin (AMRN) and Array Technologies (ARRY).

Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH."

Aurinia Pharmaceuticals' stock is owned by many different institutional and retail investors. Top institutional shareholders include Hennion & Walsh Asset Management Inc. (0.12%), Capital Investment Advisors LLC (0.03%), Douglas Lane & Associates LLC (0.01%), XR Securities LLC (0.00%), XR Securities LLC (0.00%) and Dupont Capital Management Corp (0.00%). Insiders that own company stock include Jill Leversage, Joseph M Miller, Matthew Maxwell Donley, Michael Robert Martin, Neil Solomons, Peter Greenleaf, Robert Bindert Huizinga and Stephen P Robertson.
View institutional ownership trends.

Shares of AUPH stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of AUPH stock can currently be purchased for approximately $9.37.

Aurinia Pharmaceuticals (NASDAQ:AUPH) has a market capitalization of $1.33 billion and generates $45.60 million in revenue each year. The biotechnology company earns $-180,970,000.00 in net income (profit) each year or ($0.83) on an earnings per share basis.

The company employs 300 workers across the globe.

Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The official website for the company is www.auriniapharma.com. The biotechnology company can be reached via phone at 250-708-4272, via email at ir@auriniapharma.com, or via fax at 250-744-2498.